ProCE Banner Activity

FAQs: BTK Inhibitors in MCL

Clinical Thought

Read expert answers to healthcare professionals’ questions on the current and emerging roles of BTK inhibitors in the clinical management of patients with mantle cell lymphoma.

Released: January 24, 2024

Share

Faculty

John P. Leonard

John P. Leonard, MD

Senior Associate Dean for Innovation and Initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

Ann LaCasce

Ann LaCasce, MD, MMSc

Associate Professor of Medicine
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew Lunning

Matthew Lunning, DO, FACP

Associate Professor
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Ann LaCasce, MD, MMSc

Associate Professor of Medicine
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ann S. LaCasce, MD, MMSc: consultant/advisor/speaker: Kite Pharma, Seagen.

Matthew Lunning, DO, FACP

Associate Professor
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska

Matthew Lunning, DO, FACP: consultant/advisor/speaker: AbbVie, Acrotech, ADC Therapeutics, Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EUSA, Fate Therapeutics, Genentech, Genmab, Janssen/Pharmacyclics, Kite, MorphoSys, Nurix Therapeutics, Pharmacyclics, Seattle Genetics, TG Therapeutics; researcher: Bristol Myers Squibb, Curis.

Program Director

John P. Leonard, MD

Senior Associate Dean for Innovation and Initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

John P. Leonard, MD: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Calithera, Caribou Biosciences, Constellation, Eisai, Epizyme, Genmab, Grail, Incyte, Janssen, Lilly, MEI Pharma, Merck, Mustang, Novartis, Pfizer, Roche/Genentech, Seagen, Second Genome, Sutro.